Archives
Stockholm, Sweden, May 19, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX) today announced its participation in the annual conference of the International Society for Pharmacoeconomics and Outcomes Research, ISPOR 2026, taking place May 17 to 20, 2026, in Philadelphia, PA, USA. ISPOR is a leading global conference for health economics […]
Stockholm den 13 maj, 2026. Egetis Therapeutics AB (publ) (”Egetis” eller ”Bolaget”) (Nasdaq Stockholm: EGTX) meddelade idag att medlemmar i Bolagets ledningsgrupp den 11 maj utnyttjade personaloptioner som de tilldelats i personaloptionsprogrammet 2022-2026. Detta program har ett slutdatum för utnyttjande av teckningsoptioner den 15 juni 2026. Om dessa optioner inte utnyttjas senast 15 juni 2026 […]
Stockholm, May 13, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) announces that on May 11, 2026, members of the Company’s executive management team exercised employee stock options granted under the employee stock option program (ESOP) 2022–2026. The final date for the exercise of options under ESOP 2022–2026 is June 15, […]
Stockholm den 7 maj, 2026. Egetis Therapeutics AB (publ) (”Egetis” eller ”Bolaget”) (Nasdaq Stockholm: EGTX) meddelade idag att Bolaget planerar att delta vid följande kommande medicinska konferenser under 2026: American Academy of Cerebral Palsy and Developmental Medicine (AACPDM)Philadelphia, PA, USA British Thyroid Association (BTA)London, UK Child Neurology Society (CNS)Montreal, Kanada European Society for Paediatric Endocrinology […]
Stockholm, May 7, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) today announced that the Company is planning to participate in several upcoming medical conferences in 2026, including: American Academy of Cerebral Palsy and Developmental Medicine (AACPDM)Philadelphia, PA, USA British Thyroid Association (BTA)London, UK Child Neurology Society (CNS)Montreal, Canada European Society […]
Stockholm den 5 maj 2026. Egetis Therapeutics AB (publ) (”Egetis” eller ”Bolaget”) (Nasdaq Stockholm: EGTX) meddelade idag att United States Patent and Trademark Office (USPTO) har beviljat patent nr US 12 611 383 B1 avseende Bolagets patentansökan nr 19/261,360 med titeln “Pharmaceutical Compositions for Treating MCT8 Deficiency”. Det beviljade patentet ger skydd för en ny sammansättning som innehåller […]
Stockholm, Sweden, May 5, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX) today announced that the United States Patent and Trademark Office (USPTO) granted Patent No. US 12611383B1 for the Company’s patent application No. 19/261,360 entitled “Pharmaceutical Compositions for Treating MCT8 Deficiency”. The newly granted patent provides protection for a novel […]
Stockholm, den 30 april 2026 – Egetis Therapeutics AB (publ) (”Egetis” eller ”Bolaget”) (Nasdaq Stockholm: EGTX) meddelade i dag att Bolaget kommer att delta vid Pediatric Endocrine Society (PES) Annual Meeting, som hålls den 30 april–3 maj 2026 i San Francisco, Kalifornien, USA. I samband med mötet kommer Egetis att delta i vetenskapliga och informationsrelaterade […]
Stockholm, Sweden, April 30, 2026 – Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (NASDAQ Stockholm: EGTX), today announced its participation in the Pediatric Endocrine Society (PES) Annual Meeting, taking place April 30 to May 3, 2026, in San Francisco, CA, USA. Egetis will engage with the pediatric endocrinology community through multiple scientific and educational […]
Stockholm, Sweden, April 24, 2026. Egetis Therapeutics AB (publ) (NASDAQ Stockholm: EGTX) today announced that it will publish its first quarter 2026 report on Wednesday, April 29, 2026, at 07:00 am CEST. Egetis will also host a conference call the same day at 10:00 am CEST to discuss the first quarter 2026 financial results and […]